KEDG
Evidence Grade E — Very limited evidence. 2 published studies. 1 registered clinical trial.
Testagen is a synthetic tetrapeptide from the Khavinson bioregulator programme. Despite its name (which suggests testosterone-related effects), the limited research focuses on the pituitary-thyroid axis, not testosterone. The name may create misleading expectations. No human clinical trials have been conducted and it has no regulatory approval.
2 published studies: 1 human, 0 animal, 1 in-vitro, 0 reviews
Testagen has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. An animal study using a hypophysectomised chicken model has been reported, along with in vitro cell penetration and histone interaction studies.
As with other Khavinson bioregulator peptides, the proposed mechanisms have not been independently validated. The compound's name may create misleading expectations about its proposed effects. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Testagen may penetrate cell nuclei and interact with specific DNA sequences. Cell penetration studies using fluorescence-labelled peptide in HeLa cells have been reported. Computational modelling suggests interactions with DNA regions. These observations are from in vitro and computational studies only.
Research consists almost entirely of work from the Khavinson group. The primary animal study uses a chicken model — not a mammalian model testing testosterone or testicular outcomes. No controlled human trials for testosterone or fertility endpoints exist. No pharmacokinetic data have been established. The disconnect between the compound's name and its actual research base is noteworthy. Products from unregulated channels lack pharmaceutical quality assurance.
Product Transference Study of Testagen™ TDS®-Testosterone
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
